Send to

Choose Destination
See comment in PubMed Commons below
CNS Neurol Disord Drug Targets. 2006 Apr;5(2):147-65.

Corticotropin-releasing factor receptor antagonists in affective disorders and drug dependence-- an update.

Author information

Johnson & Johnson Pharmaceuticals Research & Development, CNS Drug Discovery, B-2340 Beerse, Belgium.


Dysfunctioning of corticotropin-releasing factor (CRF) and its receptors (CRF(1) and CRF(2)) has been linked to the development of stress-related disorders, such as affective disorders and drug abuse. The molecular characterization of CRF(1) and CRF(2) receptors and their splice variants has generated detailed information on their pharmacology, tissue distribution and physiology. In addition, the recent development of a small molecule CRF(1) antagonist has provided important information on the contribution of this receptor to the development of stress-related diseases. Despite the high homology to the CRF(1) receptor and the generation of peptide-based research tools, the physiological role of the CRF(2) receptor is largely unclear. This is due to different expression patterns in rodents and primates and the lack of brain-penetrant CRF(2)-selective small molecule antagonists. However, the CRF(2) receptor may be important for motivational types of behavior essential for survival, such as feeding and defense and impacts on cardiovascular function.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Support Center